There have been no major changes in the pharmacological treatment of allergic rhinitis in recent years. Treatment is symptomatic and tailored individually, taking into account the type and severity of symptoms. Few new products have entered the market, and treatment is still largely based on antihistamines and nasally administered glucocorticoids. However, the general strategies for treating allergic rhinitis have developed over the last decade due to the introduction of the Finnish National Allergy Program. The treatment should aim at improving tolerance. Avoiding allergens is not necessary but it may help in controlling the symptoms. Hyposensitization, the only disease-modifying therapy, is a recommended, effective and safe form of treatment. New, practical sublingual hyposensitization products have facilitated treatment implementation and moved it from outpatient clinics into homes, which is a more patient-oriented approach and also cost-effective in the long term. However, the unit costs of treatment are relatively high for the patients.
近年来,过敏性鼻炎的药物治疗没有重大变化。治疗是对症的且因人而异,需考虑症状的类型和严重程度。很少有新产品进入市场,治疗仍主要基于抗组胺药和鼻用糖皮质激素。然而,由于芬兰国家过敏计划的推出,在过去十年中治疗过敏性鼻炎的总体策略有了发展。治疗应旨在提高耐受性。避免接触过敏原并非必要,但可能有助于控制症状。减敏疗法是唯一的疾病改善疗法,是一种推荐的、有效且安全的治疗形式。新型实用的舌下减敏产品促进了治疗的实施,并将其从门诊诊所转移到家庭,这是一种更以患者为导向的方法,从长远来看也具有成本效益。然而,对患者来说治疗的单位成本相对较高。